Prova Education
Prova Education designs educational programs that address a broad spectrum of gaps in awareness, attitudes, skills, and competencies related to guideline-based care and evolving disease management options. Its mission is to serve as an innovative and relevant resource for clinical content that promotes change in practice and patient outcomes.
31-45 of 125
Walmir Coutinho, MD
Marta Comas
Andreea Ciudin, MD, PhD
Personalized Obesity Management: A Comprehensive Approach
MinuteCE®Personalized Obesity Management: A Comprehensive Approach
Donna Ryan, MD
Andreea Ciudin, MD, PhD
The Power of Teamwork: Multidisciplinary Obesity Care
MinuteCE®The Power of Teamwork: Multidisciplinary Obesity Care
Andreea Ciudin, MD, PhD
Marta Comas
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD
Sandy Srinivas, MD
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Wenxin Xu, MD
Sandy Srinivas, MD
- advertisement
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®Emerging targeted therapy combination strategies in genitourinary malignancies
Ignacio Duran, MD
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®Emerging immunotherapy combination strategies in genitourinary malignancies
Sandy Srinivas, MD
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Ignacio Duran, MD
Wenxin Xu, MD
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Sandy Srinivas, MD
- advertisement
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Ignacio Duran, MD
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Wenxin Xu, MD
Sandy Srinivas, MD
